Rongchang Biotechnology (09995.HK): The National Medical Products Administration Drug Evaluation Center has granted RC148 breakthrough therapy designation for the treatment of non-small cell lung cancer.

Sinolink Financial app news, Rongchang Biotech (09995.HK) announced that the company's original research new bispecific antibody RC148 has been officially included in the breakthrough therapeutic drug category by the China National Medical Products Administration Drug Evaluation Center (CDE). The indication is as follows: RC148 combined with docetaxel for the treatment of driver gene-negative locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed treatment with PD-1/PD-L1 inhibitors and platinum-based chemotherapy (combined or sequential).